RayKnowChina Research Map
Shortlist

Enrolling by invitationLymphomaPhase not stated

Registered title, quoted from ClinicalTrials.gov

Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Eye & ENT Hospital of Fudan University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorEye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07450040, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. The target lesion has received radiation therapy or surgery (except biopsy);

    Exclusion criterion 13

  3. ECOG score 0-2 points.

    Inclusion criterion 4

  4. Patients with HCV or HIV infection and HBV infection receiving antiviral therapy at the same time are not excluded.

    Exclusion criterion 1

  5. Pregnant or lactating women.

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07450040, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Clinical diagnosis of NK/T cell lymphoma .
  • Stage I/II patients .
  • Age 18-70.
  • ECOG score 0-2 points.
  • Sign informed consent.
  • Voluntary compliance with research protocols, follow-up plans, laboratory and auxiliary examinations.

Exclusion Criteria:

  • Patients with HCV or HIV infection and HBV infection receiving antiviral therapy at the same time are not excluded.
  • Complicated with severe infection requires ICU treatment.
  • There are serious complications such as hemophagic syndrome, DIC, etc.
  • Functional impairment of major organs.
  • A history of autoimmune disease.
  • Pregnant or lactating women.
  • Patients with a history of psychotropic drug abuse who cannot abstain or have mental disorders.
  • Patients who are known to be allergic to drugs used in chemotherapy regimens.
  • Patients with other tumors requiring surgery or chemotherapy within 6 months.
  • Patients who have participated in other clinical trials within 4 weeks prior to the trial;
  • Patients who are taking other investigational drugs.
  • Patients with severe allergic history or allergic constitution.
  • The target lesion has received radiation therapy or surgery (except biopsy);
  • Previously used chemotherapy, immunotherapy or biological targeted therapy for the primary tumor.

Quoted from ClinicalTrials.gov, NCT07450040, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07450040, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07450040